iecoris cancer
Annis, incidentia et mortalitas iecoris cancer in mundo alta fuit. Rationem in regionibus progressionibus circiter 50% casuum cancri hepatis novorum quotannis, ac rate incidentium tumorum malignorum est quartus. Maxime autem aegroti cum iecoris cancer cum cirrhosi coniunguntur, vel plerique aegros tempore diagnosi progressum gradum attigerunt, et circa 20% -30% aegrorum occasiones chirurgicae resectionis accipere possunt.
Cancri hepatis curationes multae sunt, sed cancer hepaticus difficilis curatur
Surgery is the only way to cure liver cancer, and only early liver cancer has this opportunity. In addition to surgery, local treatment methods include surgery, transcatheter arterial chemoembolization, percutaneous radiofrequency ablation, and radiation therapy; systemic treatment includes chemotherapy, targeted therapy, and immunotherapy.
With the increasing number of treatments for liver cancer in recent years, precision surgical treatment combined with systemic targeted therapy (sorafenib, lervatinib, regorafenib, cabozantinib and ramozumab) and immunotherapy (Pimumab, Navumab), individualized combination therapy for patients, the treatment effect of advanced liver cancer is greatly improved.
Amet, circa 90% aegrorum cum cancro iecoris historiam hepatitis B, 5% -8% aegrorum cum cancro iecoris hepatitis C infici, et circiter 3% aegrorum cum cirrhosi causato alcoholismo chronici, hepatis pingue atque autoimmune morborum hepatis relato.
Clinically, the curse of the three-step model (HBV-cirrhosis-liver cancer) has always threatened many domestic liver cancer patients, making many cutting-edge treatment methods unable to improve the current status of liver cancer treatment. New therapies are urgently needed to solve the hepatitis B-related iecoris cancer curatio.
T cellas instruendi cum antigenis novis armis specialibus
Investigatores in Hospitali Nationali Duce-Singapore designaverunt Hepatitis B virus specialium T cellulas ut carcinoma hepatitis B-type hepatocellulares tractare, genus cancri hepatis in Asia commune.
Researchers have individualized T cells to make T cells specific to patients. I think this is a CAR-T-like cellular immunotherapy, which is to advance specific antigens of tuberculum cells by technical means to activate them. T cells, after activated T cells are infused back into the body, it is like updating the weapon scouts to precisely attack cancer cells.
Manipulus duos aegros cum hepatitis transplantationis iecoris cum peculiaribus T-cellulis feliciter tractavit, quorum duo antea cancro hepatitis B virus iecoris infecti sunt, et nunc post translationem iecoris relapsi sunt. Post specifica T cellae curationem, unus aegrorum reductionem in umbilico tumoris vidit.
Scopum antigen est HBV-DNA
In justo personali, investigatores specificae HBV-DNA exemplaria integrationis enucleatae in cellulis cancri iecoris cuiusque patientis, et deinde texit, designaverunt et discesserunt cellulas T individuatae, et deinde tractatae sunt. Plus quam 20 T transfusiones cellae bene factae sunt in duobus aegris iecoris traducere, et hae cellulae machinatae T tumores destruere poterant.
Senior indagator Antonius Bertoletti dixit: Componentes gene HBV-DNA integrata HBV-specificas T cellulas functiones movere possunt et hepatitis speciales iecoris cancri cellulas necare sine affectibus aliis cellulis salubribus. Nullae reactiones adversae curatio relatae erant, et metastasis longinqui cancer in uno aegro etiam significantem reductionem habuit.
Pulmonis cancer caused by chronic hepatitis B infection accounts for 80% of all liver cancers in Asian lung cancer, and the treatment prognosis is not ideal. Especially in patients with liver cancer recurrence after liver transplantation, treatment options are more limited.
Curatio specifica T cellae a Collegio Medical Nationali Singapore evoluta est ut meliorem salutem et qualitatem vitae huius speciei patientis efficiat. CAR T-cell Lorem spes nova est in futuro vincendi cancer!
CAR T-cell Lorem est Chimeric Antigen Receptor T-Cell Immunotherapy. Hoc est novum genus accuratae iaculis justo pro tumoribus tractandis. Nuper, bonum consequitur curatio tumore clinica per ipsum et emendationem. Valde promissum est, accurate, celeriter, efficax, et cancrum sanare potest. Novi tumoris immunotherapy.
Ut legere licet: Car T-Lorem in India
CAR T-Lorem Est methodus curationis cancer, quae recentibus annis interruptiones significantes consecutus est, et approbata a pertinentibus Dicasteriis internationalibus pro usu clinico in curatione tumorum hematologicorum. Praeterea iudiciis clinicis CAR-T cellae therapiae solidorum tumores in plena adductione sunt.
